The stock of Citius Oncology Inc (CTOR) has gone down by -1.84% for the week, with a 10.38% rise in the past month and a -90.32% drop in the past quarter. The volatility ratio for the week is 10.76%, and the volatility levels for the past 30 days are 12.02% for CTOR. The simple moving average for the past 20 days is 5.25% for CTOR’s stock, with a -86.14% simple moving average for the past 200 days.
Is It Worth Investing in Citius Oncology Inc (NASDAQ: CTOR) Right Now?
Citius Oncology Inc (NASDAQ: CTOR) has a higher price-to-earnings ratio of 4.87x compared to its average ratio, The 36-month beta value for CTOR is at 0.07.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CTOR is 0.35M, and currently, shorts hold a 3.03% of that float. The average trading volume for CTOR on November 06, 2024 was 257.93K shares.
CTOR) stock’s latest price update
Citius Oncology Inc (NASDAQ: CTOR)’s stock price has gone rise by 15.74 in comparison to its previous close of 1.03, however, the company has experienced a -1.84% decrease in its stock price over the last five trading days.
CTOR Trading at -14.42% from the 50-Day Moving Average
After a stumble in the market that brought CTOR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -97.57% of loss for the given period.
Volatility was left at 12.02%, however, over the last 30 days, the volatility rate increased by 10.76%, as shares surge +15.53% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -41.67% lower at present.
During the last 5 trading sessions, CTOR fell by -2.01%, which changed the moving average for the period of 200-days by -88.85% in comparison to the 20-day moving average, which settled at $1.1325. In addition, Citius Oncology Inc saw -89.10% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CTOR
Equity return is now at value 3.35, with 3.25 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 0.01.
Conclusion
In conclusion, Citius Oncology Inc (CTOR) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
